Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
505 results
  • Intranasal Spray Formulation Containing Rizatriptan benzoate for the Treatment of Migraine. [Journal Article]
    Int J Pharm 2019; :118702Chokshi A, Vaishya R, … Potta T
  • Rizatriptan produces antimigraine activity by acting as selective agonist of 5-HT1B and 5-HT1D receptors present on intracranial and extracerebral blood vessels. Absorption from oral tablet is slow with Tmax of approximately 1-1.5 hours. A few attempts have been made to promote rapid absorption such as oral or sublingual films with limited success. The aim of our study was to develop intranasal s…
  • StatPearls: Almotriptan [BOOK]
    StatPearls Publishing: Treasure Island (FL) Sidhu Gursharan G Avalon University School of Medicine Patel Priti P Un of Florida College of Pharmacy BOOK
  • Almotriptan is the first FDA-approved drug used to treat migraine headaches in adults with or without an aura.[1] The drug is also useful in adolescents with a history of a migraine that, when left untreated, lasts 4 hours or longer. Certain triptan medications such as almotriptan and rizatriptan have also been shown to be effective and safe for management of acute migraines and other benign head…
  • Drug repurposing for Dravet syndrome in scn1Lab-/- mutant zebrafish. [Journal Article]
    Epilepsia 2019; 60(2):e8-e13Sourbron J, Partoens M, … de Witte P
  • Dravet syndrome (DS) is a severe genetic epileptic encephalopathy with onset during the first year of life. Zebrafish models recapitulating human diseases are often used as drug discovery platforms, but also for drug repurposing testing. It was recently shown that pharmacological modulation of three serotonergic (5-HT) receptors (5-HT1D , 5-HT2C , 5-HT2A) exerts antiseizure effects in a zebrafish…
  • Pharmacotherapy for acute migraines in children and adolescents. [Review]
    Expert Opin Pharmacother 2019; 20(4):455-463Barbanti P, Grazzi L, Egeo G
  • Migraine is increasingly recognized as an extremely burdensome and disabling disorder in both children and adolescents. A proper treatment plan is needed to improve the quality of life of both children and families as well as to minimize the risk of disease progression.
  • Pediatric and Adolescent Headache. [Review]
    Continuum (Minneap Minn) 2018; 24(4, Headache):1108-1136Gelfand AA
  • This article provides the practicing neurologist with a comprehensive, evidence-based approach to the diagnosis and management of headache in children and adolescents, with a focus on migraine.
New Search Next